PTCT241115P39000
- 1.30
- 0.000.00%
PTC Therapeutics Newsroom
Morgan Stanley Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Maintains Target Price $45
Baird Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $48
PTC Therapeutics Analyst Ratings
PTC Therapeutics: Strong Q3 Performance Amid Market and Regulatory Challenges, Holds Rating Amid Mixed Future Outlook
William Blair Maintains PTC Therapeutics(PTCT.US) With Buy Rating
William Blair Sticks to Its Buy Rating for PTC Therapeutics (PTCT)
Citi Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Maintains Target Price $26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NRIX) and PTC Therapeutics (PTCT)
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Cuts Target Price to $30
PTC Therapeutics Analyst Ratings
Morgan Stanley Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Raises Target Price to $45
Morgan Stanley Boosts Price Target on PTC Therapeutics to $45 From $32, Keeps Equalweight Rating
Raymond James Maintains PTC Therapeutics(PTCT.US) With Hold Rating
Leerink Partners Maintains PTC Therapeutics(PTCT.US) With Hold Rating
Maintain Position on PTC Therapeutics Amidst Uncertainties and NDA Delay: Schwartz's Hold Rating
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT) and Accolade (ACCD)
Goldman Sachs Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Announces Target Price $32
Sell Rating on PTC Therapeutics Amid Regulatory Uncertainties and Efficacy Concerns
PTC Therapeutics Analyst Ratings
William Blair Maintains PTC Therapeutics(PTCT.US) With Buy Rating